Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

(2019) Takuro Yamamoto et al.   BREAST CANCER RESEARCH AND TREATMENT

Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway

(2019) Lin Chen et al.   MEDICAL SCIENCE MONITOR

Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer

(2018) Naveen K.R. Chalakur-Ramireddy et al.   BIOSCIENCE REPORTS

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

(2018) Ricardo L. B. Costa et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts

(2018) Xiaodong Ma et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Cyclin D1 depletion interferes with oxidative balance and promotes cancer cell senescence

(2018) Phatthamon Laphanuwat et al.   JOURNAL OF CELL SCIENCE

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Effects of Different mTOR Inhibitors in EGFR Inhibitor Resistant Colon Carcinoma Cells

(2018) Tamás Sticz et al.   PATHOLOGY & ONCOLOGY RESEARCH

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma

(2017) T Fujishita et al.   ONCOGENE

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

(2017) Seraina Faes et al.   Oxidative Medicine and Cellular Longevity

Triple-negative breast cancer and the potential for targeted therapy

(2017) Jing-Ru Jhan et al.   PHARMACOGENOMICS

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity

(2017) Judith Schaffrath et al.   PLoS One

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

(2016) Qing-Bai She et al.   BMC CANCER

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis

(2016) J Musa et al.   ONCOGENE

Activity, assay and target data curation and quality in the ChEMBL database

(2015) George Papadatos et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

eIF2α phosphorylation as a biomarker of immunogenic cell death

(2015) Oliver Kepp et al.   SEMINARS IN CANCER BIOLOGY

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer

(2014) Julie M. Madden et al.   BREAST CANCER RESEARCH AND TREATMENT

Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer

(2014) Christiana S. Kappler et al.   Molecular Oncology

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Target identification and mechanism of action in chemical biology and drug discovery

(2013) Monica Schenone et al.   Nature Chemical Biology

mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors

(2011) S. Walsh et al.   BREAST

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells

(2011) T. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells

(2010) Steffen Wedel et al.   CANCER LETTERS

Triple-negative breast cancer: Present challenges and new perspectives

(2010) Franca Podo et al.   Molecular Oncology

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

(2009) Eva Juengel et al.   BMC CANCER

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Arginine Deprivation as a Targeted Therapy for Cancer

(2008) L. Feun et al.   CURRENT PHARMACEUTICAL DESIGN

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

(2008) Bing-Hua Jiang et al.   DRUG RESISTANCE UPDATES